ESC 365 - Low dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: the BARACK-D randomised trial

ESC Professional Premium Access

Low dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: the BARACK-D randomised trial

Session: Nature Medicine: 2024 highlights in personalised cardiovascular medicine

Topic: e-Cardiology/Digital Health

Speaker: Doctor N. Jones (Oxford, GB) Professor R. Hobbs (Oxford, GB)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speakers

Doctor Nicholas Jones

University of Oxford, Oxford (United Kingdom of Great Britain & Northern Ireland)

1 presentation

0 follower

Professor Richard Hobbs

Oxford (United Kingdom of Great Britain & Northern Ireland)

10 presentations

0 follower

3 more presentations in this session

An evidence-based screening tool for heart failure with preserved ejection fraction: the HFpEF-ABA score

Speaker: Assistant Professor Y. Reddy (Rochester, US)

Proteomic analysis of cardiorespiratory fitness for prediction of mortality and multi-system disease risks

Speaker: Doctor A. Perry (Nashville, US)

Artificial intelligence-enabled electrocardiography alert intervention and all-cause mortality: a pragmatic randomised clinical trial

Speaker: Professor C. Lin (Taipei, TW)

Access the full session

Nature Medicine: 2024 highlights in personalised cardiovascular medicine

Speakers: Doctor N. Jones, Professor R. Hobbs, Assistant Professor Y. Reddy, Doctor A. Perry, Professor C. Lin

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources